Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL71899 | 1.00 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL28977209 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL21357686 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL557242 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL41543 | 0.98 | CYP3A4 (0.39) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Water SCHEMBL28537381 | 0.96 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrogen Peroxide SCHEMBL3706944 | 0.94 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Carbon Tetrachloride SCHEMBL29029110 | 0.91 | ALDH1A1 (0.33) | CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL5803242 | 0.83 | CYP3A4 (0.49) | CYP3A4HSD17B10MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL22499931 | 0.79 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159920-A1 | METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATING THERAPIES FOR TREATING CANCERS AND RELATED DISORDERS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3990119-A1 | METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATING THERAPIES FOR TREATING CANCERS AND RELATED DISORDERS | Fred Hutchinson Cancer Research Center (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3498311-B1 | IMPLANT AND METHOD OF PRODUCING AN IMPLANT | VIDEREGEN LTD (GB) | 2021-10-13 | — | — | EP | disclosed |
| US-20210236638-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2021-08-05 | — | — | US | disclosed |
| US-10933134-B2 | Combination therapies for treatment of cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020264177-A1 | METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATING THERAPIES FOR TREATING CANCERS AND RELATED DISORDERS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2874674-B1 | IMPLANT AND METHOD FOR PRODUCING AN IMPLANT | VIDEREGEN LTD (GB) | 2020-10-14 | — | — | EP | disclosed |
| EP-3498311-A1 | IMPLANT AND METHOD OF PRODUCING AN IMPLANT | Videregen Limited (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10226547-B2 | Implant and method for producing an implant | VIDEGREN LIMITED (GB) | 2019-03-12 | — | — | US | disclosed |
| CN-104703634-B | Implant and method for producing an implant | 威德瑞真有限公司 | 2018-12-11 | — | — | CN | disclosed |
| WO-2003006006-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS TO MITIGATE NERVE DAMAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-01-23 | — | — | WO | disclosed |
| US-6479250-B1 | Eck receptor ligands | AMGEN INC. | 2002-11-12 | — | — | US | disclosed |
| US-6395874-B1 | A PROTEIN; THERAPY FOR STROKES, ARTHRITIS, PULMONARY ADULT RESPIRATORY DISTRESS SYNDROME, ATHEROSCLEROSIS AND INFLAMMATION OF THE EYE | DOHENY EYE INSTITUTE | 2002-05-28 | — | — | US | disclosed |
| CN-1305383-A | Regulation of tyrosine bydroxylase | NEURONZ LTD (NZ) | 2001-07-25 | — | — | CN | disclosed |
| US-6087167-A | PROMOTING NEURON SURVIVAL OR NEURITE OUTGROWTH BY CONTACTING NEURONS WITH AN AMOUNT OF AN ECK RECEPTOR BINDING PROTEIN OF SPECIFIC AMINO ACID SEQUENCE | AMGEN INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0594739-B1 | CANCER TREATMENT | ANTISOMA RES LTD (GB) | 2000-03-01 | — | — | EP | disclosed |
| US-5824303-A | DNA SEQUENCE ENCODING, PROTEINS AND PEPTIDES | AMGEN INC. (US) | 1998-10-20 | — | — | US | disclosed |
| WO-1996036713-A2 | ECK RECEPTOR LIGANDS | AMGEN INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0594739-A1 | CANCER TREATMENT | ANTISOMA RESEARCH LIMITED (GB) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993000927-A1 | CANCER TREATMENT | ANTISOMA LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10933134-B2 | Combination therapies for treatment of cancer | BPHL, FOLH1, PSAP | CYP3A4 1420/4885TDP1 1758/4885ALDH1A1 733/4885 |
| US-20210236638-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | BPHL, FOLH1, PSAP | CYP3A4 1420/4885TDP1 1758/4885ALDH1A1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.